SpectraCure is conducting a Phase 1 clinical study for the treatment of patients with relapse in prostate cancer, using the company's photodynamic therapy (PDT) technology. As previously announced, the maximum and final dose of the drug dose product has been reached in the study. During post-treatment follow-up, the PSA value (Prostate-specific antigen) of the patient is monitored regularly. PSA is a blood marker that may indicate the presence of a cancer tumour in the prostate. The last treated patient had a PSA value of 4.9 ng/ml prior to treatment. At the last follow-up visit, the PSA value had dropped to 0.3 ng/ml, indicating that the tumour is eradicated.
The CTO of SpectraCure Johannes Swartling will give a talk about the company at a seminar in Kista in connection with Photonics Sweden's conference on Optics & Photonics, on 17 October 2017. The lecture will mainly present the company in general terms, and the current preliminary results from the clinical study will be addressed. The lecture is aimed at an audience of researchers and industry representatives in photonics. The seminar requires registration.
SpectraCure has previously communicated that MRI imaging (MRI) of the prostate acquired one week after treatment at the highest drug dose suggested that the treatment had had the intended effect, i.e. the images showed a clear change in gland and tumour area as a result of the PDT treatment, which could be interpreted to mean that the tissue had been knocked out.
It should be emphasized that the main objective of the Phase 1 study is to demonstrate the safety of the SpectraCure treatment method and to establish the correct dose level. These preliminary results also suggest that the method has had the intended effect, which is a secondary target for the Phase 1 study.
